Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Dec 20:10:357.
doi: 10.1186/1471-2334-10-357.

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Pierre Van Damme  1 , Anna Moiseeva, Igor Marichev, Anne-Diane Kervyn, Robert Booy, Sherine Kuriyakose, Andrew Brockway, Su-Peing Ng, Maarten Leyssen, Jeanne-Marie Jacquet
Affiliations
Randomized Controlled Trial

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Pierre Van Damme et al. BMC Infect Dis. .

Abstract

Background: The standard three-dose schedule of hepatitis B vaccines is frequently not completed, especially in adolescents. A primary study has confirmed the equivalence of a two-dose schedule of an Adult formulation of hepatitis B vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in adolescents (11-15 years) [Group HBV_3D]. This follow-up study evaluated the five year persistence of antibody response and immune memory against the hepatitis B surface (anti-HBs) antigens five years after completion of primary vaccination.

Methods: A total of 234 subjects returned at the Year 5 time point, of which 144 subjects received a challenge dose of hepatitis B vaccine. Blood samples were collected yearly and pre- and post-challenge dose to assess anti-HBs antibody concentrations.

Results: At the end of five years, 79.5% (95% confidence interval [CI]: 71.7 - 86.1) and 91.4% (95% CI: 82.3 - 96.8) of subjects who received the two-dose and three-dose schedules, respectively had anti-HBs antibody concentrations ≥ 10 mIU/mL. Post-challenge dose, all subjects had anti-HBs antibody concentration ≥ 10 mIU/mL and >94% subjects had anti-HBs antibody concentration ≥ 100 mIU/mL. All subjects mounted a rapid anamnestic response to the challenge dose. Overall, the challenge dose was well-tolerated.

Conclusion: The two-dose schedule of hepatitis B vaccine confers long-term immunogenicity and shows evidence of immune memory for at least five years following vaccination.

Trial registration: Clinical Trials NCT00343915, NCT00524576.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
Percentage of subjects with anti-HBs concentration ≥10 mIU/mL at all long-term follow-up time points (Long-term ATP cohort for immunogenicity).
Figure 3
Figure 3
Evolution of anti-HBs antibody geometric mean concentrations (GMCs) during the five years follow-up period (Long-term ATP cohort for immunogenicity) and during the challenge phase (ATP cohort for immunogenicity).
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Position paper on Hepatitis B. Wkly Epidemiol Rec. 2009;84:405–420. - PubMed
    1. Gold Y, Somech R, Mandel D, Peled Y, Reif S. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. Acta Paediatrica. 2003;92:1158–1162. doi: 10.1111/j.1651-2227.2003.tb02477.x. - DOI - PubMed
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hep. 2004;11:97–107. doi: 10.1046/j.1365-2893.2003.00487.x. - DOI - PubMed
    1. Heron L, Selnikova O, Moiseieva A, Van Damme P, Van der Wielen M, Levie K, Hoet B, Stoffel M. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: A randomised controlled trial. Vaccine. 2007;25:2817–2822. doi: 10.1016/j.vaccine.2006.12.021. - DOI - PubMed
    1. Centers for Disease Control and Prevention (CDC) Global progress toward universal childhood hepatitis B vaccination. MMWR Morb Mort Wkly Rep. 2003;52:868–870. - PubMed

Publication types

Substances

Associated data